Nanyang Biologics and Precisya Global Inc Announce Strategic Collaboration to Validate Natural Compounds Against Genetic Disease Markers
Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI's genomic big data analytics with NYB's natural compound libraries and AI capabilities.
